Loading organizations...
§ Private Profile · Paris, France
Solence is a technology company.
Solence develops a digital health support tool engineered to assist individuals in managing chronic hormonal conditions. The company provides a personalized program that integrates educational content with practical guidance, focusing on lifestyle adjustments. This solution is specifically tailored to address conditions such as Polycystic Ovary Syndrome, helping patients with symptom management and fertility improvement through evidence-based approaches.
The company was established in 2022 in Strasbourg, France, by co-founders Clara Stephenson and Mael Mertad. Their foundational insight stemmed from the unmet need for structured, accessible support for those grappling with hormonal imbalances, particularly the complex challenges faced by PCOS patients. Stephenson and Mertad aimed to bridge this gap by offering a programmatic approach to health management.
Solence primarily serves patients diagnosed with PCOS, empowering them to implement lifestyle changes crucial for symptom management and fertility improvement. The company's vision centers on enabling individuals to take proactive control over their health, fostering better long-term outcomes and an enhanced quality of life through comprehensive digital support.
Solence has raised $2.0M across 1 funding round.
Solence has raised $2.0M in total across 1 funding round.
Solence has raised $2.0M in total across 1 funding round.
Solence's investors include Reach Capital, Charles Gorintin, Chris M. Willliams, Jean Charles Samuelian, Karim Atiyeh, Berthe Latreille, Celine Lazorthes, Stephane Mardel, Bpifrance, Yonca Braeckman.
Solence has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2025 | $2M Seed | — | Reach Capital, Charles Gorintin, Chris M. Willliams, Jean Charles Samuelian, Karim Atiyeh, Berthe Latreille, Celine Lazorthes, Stephane Mardel, Bpifrance, Yonca Braeckman | Announced |
# Solence: AI-Driven Digital Therapeutics for PCOS
Solence is a femtech company that develops AI-powered digital therapeutics to address Polycystic Ovary Syndrome (PCOS), a hormonal condition affecting up to 20% of women worldwide.[2] Founded in 2022 by Clara Stephenson, the Paris-based startup creates patient-centric care solutions designed to help women manage PCOS symptoms through personalized lifestyle interventions rather than relying solely on pharmaceutical treatment.[1] The company's flagship product is a mobile app offering a twelve-week program grounded in peer-reviewed research, enabling women to address PCOS "beyond the pill" through tailored digital therapeutics.[2]
Solence addresses a critical gap in women's healthcare: while 85% of women with PCOS lack adequate support, the condition causes significant quality-of-life impacts including weight gain, irregular periods, mental health struggles, and workplace difficulties.[2] The company's mission extends beyond symptom management to increasing healthy life expectancy for women by reducing the burden of chronic conditions through lifestyle-based and AI-powered interventions.[1]
Clara Stephenson founded Solence after a decade-long personal struggle with undiagnosed PCOS during her career as a corporate lawyer at Ernst & Young.[2] Her diagnosis emerged during fertility investigations, which revealed both the long-term condition and potential infertility risks—a pivotal moment that redirected her professional trajectory.[2]
Before launching Solence, Stephenson created Les Natives, a PCOS-focused health and wellness blog born during the COVID pandemic where she shared her personal experiences.[1] The blog gained substantial traction, accumulating over 135,000 visits and building a committed online community of more than 8,000 followers.[1] This organic validation of demand—demonstrating genuine interest in PCOS education and support—provided the foundation for Solence's launch and validated the market opportunity.[1]
Solence operates at the intersection of three significant trends: the femtech movement, the digital therapeutics revolution, and the chronic disease management shift. Women's health has historically been underfunded and under-researched relative to disease prevalence, making femtech startups increasingly attractive to impact-focused investors.[1] The company's €1.6M seed round—backed by Impact Shakers Ventures and notable angels including Céline Lazorthes (founder of Mangopay and Leetchi)—reflects growing capital recognition of women's health as both a social imperative and commercial opportunity.[1]
Solence also exemplifies the broader healthcare trend toward digital-first, preventive care models that reduce reliance on pharmaceutical interventions. As healthcare systems globally grapple with chronic disease burden and medication costs, software-based therapeutic solutions offer scalable alternatives. By targeting PCOS—affecting hundreds of millions of women—Solence addresses a condition with massive addressable market potential and minimal existing digital solutions.[2]
Solence is positioned to become a category leader in digital PCOS care, with immediate priorities focused on deepening app functionality, expanding clinical partnerships, and scaling distribution.[1] The company's success will depend on clinical validation of its AI-driven interventions and ability to integrate with existing healthcare systems to reach the 85% of PCOS patients currently underserved.[2]
Looking forward, Solence's model—combining founder expertise, data-driven personalization, and lifestyle-first treatment—could extend beyond PCOS to other hormone-related and metabolic conditions affecting women. As digital therapeutics gain regulatory acceptance and reimbursement pathways mature, companies like Solence that combine clinical rigor with user-centric design will likely shape the future of chronic disease management. The timing is favorable: investor appetite for femtech is rising, digital health adoption has normalized post-pandemic, and PCOS awareness is growing—creating a convergence that could accelerate Solence's path to impact and scale.